Recombinant Polyclonal Proteins for Consistent High-Titer Immunity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing vaccine-induced immune responses are inadequate in certain populations, leading to increased infection risk, and current antibody replacement therapies like IVIg and hyperimmunes suffer from variability and low pathogen titers, making them difficult to manufacture at scale and inconsistent in effectiveness.
Innovation Solution
Development of recombinant polyclonal proteins (RPPs) derived from peripheral blood plasma cells or plasmablasts mobilized by vaccines, which are specifically separated and combined to form libraries with high antibody diversity and specificity for various antigens, including vaccines, viruses, and bacteria, to enhance immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If passive immunization with IVIg or hyperimmunes is used to protect immunodeficient patients, then protective immunity is provided, but the antibody titers are low and inconsistent, leading to significant morbidity and mortality
Solution Approach 1:
The patent creates recombinant copies of antibodies by isolating antibody-encoding genes from vaccinated donors and expressing them in mammalian cells. This copying process allows the production of consistent, high-titer antibodies that replicate the protective immunity of hyperimmune donors without relying on plasma donation variability.
Solution Approach 2:
The patent changes the production parameters from plasma-derived extraction to recombinant expression systems. By transforming the production method and using vaccinated donors as gene sources followed by cellular expression, the system achieves both high titer and consistency in antibody production.
2Productivity
If hyperimmune plasma is derived from multiple donors to scale commercially, then production volume increases, but lot-to-lot variability increases and manufacturing consistency decreases
Solution Approach 1:
Instead of combining plasma from multiple donors which creates variability, the patent copies the antibody genes into identical mammalian cell lines. This allows scalable production through cell culture expansion while maintaining lot-to-lot consistency, as each batch is produced from the same engineered cell line.
Solution Approach 2:
The patent segments the manufacturing process into gene isolation, vector construction, and cellular expression stages. This segmentation allows for standardized protocols at each stage, ensuring that scaling production does not compromise manufacturing precision.
3Quantity of substance
If larger doses of IVIg are administered to increase anti-pathogen titers, then antibody quantity increases, but treatment cost and patient burden increase
Solution Approach 1:
The recombinant antibody production system generates high titers of antibodies in controlled cell cultures, eliminating the need for high-dose IVIg administration. The copied antibody genes are expressed at high levels in mammalian cells, providing sufficient antibody quantity at therapeutic doses.
Data Source
AI summary
Provided herein are compositions comprising recombinant polyclonal proteins (RPPs) derived from mammalian plasma cells and plasmablasts. Also provided are methods of using the RPPs.